CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment
Lock and colleagues engineered CAR’TCR-T cells, co-expressing a CD33-CAR and a transgenic dNPM1-TCR. The study aims to enhance the efficacy of existing cell therapies for acute myeloid leukemia, a pressing concern given the substantial relapse rates in half of affected patients. CAR’TCR-T cells were required for complete tumor elimination in vivo.